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A B S T R A C T
Foot-and-mouth disease virus (FMDV) is an important pathogen that affects livestock breeding and causes huge
economic losses worldwide. Currently, the development of antiviral agents to combat FMDV infection at the
early stages is being explored. As viral replication critically depends on the host for nucleoside supply, host
enzymes involved in nucleotides biosynthesis may represent potential targets for the development of antiviral
agents. In the present study, the effects of IMP dehydrogenase (AVN-944 and mycophenolate mofetil) and di-
hydroorotate dehydrogenase (teriflunomide) inhibitors were evaluated both in vitro and in vivo. The results
revealed that these compounds were effective in suppressing FMDV (O/MY98/BY/2010 and A/GD/MM/2013)
infection. With regard to the antiviral mechanism, time-of-addition experiments revealed that these compounds
were effective when added at the early stages of viral lifecycle (0–8 h post infection). However, exogenous
guanosine/uridine eliminated the antiviral activity of these compounds. Importantly, treatment AVN-944 and
teriflunomide significantly improved the survival of mice that were subcutaneously treated with FMDV.
Together, the results of the present study indicate the broad-spectrum activities of anti-FMDV agents targeting
IMP dehydrogenase or dihydroorotate dehydrogenase, which could be useful in developing strategies to prevent
FMD.
1. Introduction
Foot-and-mouth disease (FMD) is one of the highly contagious dis-
eases of domestic and wild cloven-hoofed animals, such as cattle, swine,
sheep, goats, and deer. The causative agent, FMD virus (FMDV), rapidly
replicates in the host and spreads to susceptible animals in contact [1].
The common symptoms of FMD include fever, lethargy, and appearance
of vesicular lesions in tongue, feet, snout, and teats, resulting in high
morbidity and low mortality in adult animals, and high mortality in
young animals because the disease can affect the heart [2]. The FMDV
is the type species of the genus Aphthovirus belonging to the Picorna-
viridae family, and contains a single-stranded, positive-sense RNA
genome of approximately 8500 bases surrounded by an icosahedral
capsid with 60 copies each of four structural proteins, VP1–4. The virus
is antigenically highly variable and consists of seven serotypes, in-
cluding O, A, C, Asia 1, South African Territories (SAT) 1, SAT 2, and
SAT 3, with multiple subtypes in each serotype [3]. Serotype O is the
most common worldwide and has been responsible for much of the
reported economically devastating disease occurrence [4,5]. The cur-
rently available measures for controlling and preventing FMD mainly
comprise vaccination. However, vaccines are ineffective in controlling
complicated outbreaks or genetic variants of the virus. Therefore, there
is an urgent need to develop specific antiviral strategies against FMDV
for providing early protection from the disease, as well as determine
alternative methods of applying antiviral agents to reduce the spread of
FMDV in outbreak situations [6].
Cellular nucleotides, composed of purines and pyrimidines, are
important constituents of RNA and DNA, and viruses heavily rely on
specific host factors, such as nucleosides, to complete their lifecycles.
Therefore, disruption of enzymes involved in nucleosides biosynthesis
in hosts may represent a potential antiviral strategy. Inosine mono-
phosphate dehydrogenase (IMPDH), a key enzyme in the de novo
synthesis of purines, is widely conserved in living organisms [7]. This
enzyme catalyzes a rate-limiting step essential for the de novo synthesis
of guanosine monophosphate (GMP) and ultimately the nucleotide
guanosine triphosphate (GTP) [8]. Two isoforms of IMPDH, type I and
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II with 84% amino acids identity, have been identified in humans. As
inhibition of IMPDH can deplete guanine nucleotide pools, followed by
a decrease in DNA and RNA synthesis, this enzyme could be a good
candidate for use as an antiviral agent. IMPDH has been employed as a
target in immunosuppressive therapy, as an antiangiogenic agent, and
as an antiviral drug [9,10]. Dihydroorotate dehydrogenase (DHODH) is
sequentially the fourth and rate-limiting enzyme in the de novo bio-
synthesis pathway of pyrimidines. Located in the inner membrane of
mitochondria, DHODH can convert dihydroorotate to orotate, which is
subsequently utilized by the multifunctional uridine monophosphate
(UMP) synthase to produce UMP. The inhibition of pyrimidines bio-
synthesis has also been explored as a strategy in rheumatology and
oncology for treating various infectious diseases, cancers, and im-
munological disorders [11,12].
In the present study, we evaluated the effects of two IMPDH in-
hibitors (AVN-944 and mycophenolate mofetil) and one DHODH in-
hibitor (teriflunomide) on FMDV replication in vitro, and then identi-
fied their preliminary modes of action. Besides, the antiviral activities




IBRS-2 cells were cultured in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10% fetal bovine serum (FBS) and 1%
penicillin-streptomycin at a temperature of 37 °C with 5% CO2. The
virus strains of serotype O (O/MY98/BY/2010) and A (A/GD/MM/
2013) FMDV used in the present study were derived from Lanzhou
Veterinary Research Institute, Chinese Academy of Agriculture
Sciences. AVN-944, mycophenolate mofetil (MF), and teriflunomide
(Fig. 1), guanosine and uridine were all products of MCE. Rabbit hyper-
immune serum raised against O/MYA98/BY/2010 were prepared in our
laboratory. PrimeScript™ RT reagent kit containing gDNA Eraser and
SYBR Premix Ex Taq™II (Tli RNaseH Plus) used for Q-PCR experiment
was purchased from TaKaRa (Dalian, China). All the other agents used
in this report were commercially available.
2.2. Ethics statements
All animal experiments were performed in a Biosafety level-3 la-
boratory and approved according to the requirements of the Animal
Ethics Committee of Lanzhou Veterinary Research Institute, Chinese
Academy of Agricultural Science (No. LVRIAEC2018-007).
2.3. Cell viability assay
The potential cytotoxicity of compounds against IBRS-2 cells was
determined by MTS assay (Abcam, USA) according to the manu-
facturer’s instructions. Briefly, the IBRS-2 cells were cultured in 96-well
plate at a density of 3×104 cells/well, and various concentrations of
AVN-944, mycophenolate mofetil, and teriflunomide (100–500 μM)
were respectively added. After incubation for 72 h at 37℃ in 5% CO2
atmosphere, 20 μL of MTS were added to each well for another 4 h at
37℃. Then, the absorbance of each well at 490 nm was determined by
using ELISA reader.
2.4. Antiviral activity assay
The antiviral activity of the compounds was determined based on
cytopathic effect (CPE) reduction by MTS assay. One day prior to in-
fection, 3×104 IBRS-2 cells/well were seeded onto a 96-well culture
plate. The next day, the medium was removed and cells were washed
with PBS. Subsequently, 100 TCID50 of FMDV (O/MY98/BY/2010 and
A/GD/MM/2013) were added to the cells for 1 h, respectively.
Afterwards, 0.1 mL of medium supplemented with FBS containing ap-
propriate concentration of the test compounds were added to the cells
to generate appropriate CPE for 48 h after infection. Four wells were
used as viral controls (virus-infected cells that were not treated with the
compounds), while another four wells were employed as cell controls
(non-infected cells that were not treated with the compounds). The
absorbance of each well was determined by a plate reader at 490 nm.
The results were quantified as a percentage of the controls, and the 50%
effective concentration (EC50) values were graphically obtained using
GraphPad software. The percent protection (expressed in %) achieved
by the test compounds in FMDV-infected cells was calculated as follows:
{(ODt)FMDV − (ODc)FMDV}/{(ODc)mock − (ODc)FMDV}×100,
where (ODt)FMDV is the optical density of FMDV-infected cells treated
with a given test compound, (ODc)FMDV is the optical density of the
control untreated FMDV-infected cells, and (ODc)mock is the optical
density of the control untreated mock-infected cells. The antiviral ac-
tivity was presented as % of control. DMSO was used as a negative
control. The cell culture supernatants were collected at 48 h post-in-
fection for the detection of FMDV 2B mRNA by Q-PCR. For nucleosides
supplementation, IBRS-2 cells (3× 105 cells/well) were plated in 12-
well plates and treated as described earlier [13]. The samples were
collected at 48 h post-infection.
2.5. Time-of-Addition assay
The time-of-addition effect was examined as previously described
[14]. In brief, 2× 105 IBRS-2 cells/well were seeded onto 12-well
culture plates and incubated for 24 h. Then, the confluent monolayer
was infected with FMDV for 1 h and treated with the test compounds
(added into the wells) either concurrently during FMDV infection (0 h)
or at intervals of 2, 4, 8, and 16 post-infection. After incubation at 37 °C
for 48 h, samples were collected and the reduction in viral 2B mRNA
levels and VP1 protein was determined by Q-PCR and Western blot
analysis, respectively.
2.6. Indirect immunofluorescence assay
The IBRS-2 cells infected with FMDV in a 12-well plate were fixed
with 4% paraformaldehyde, permeabilized with 0.5% Triton X-100 (in
PBS), blocked with 1% bovine serum albumin (BSA) for 0.5 h, and then
incubated with primary antibody (rabbit hyperimmune serum) for 1 h,
followed by appropriate peroxidase-conjugated goat anti-rabbit IgG
(H+ L) for 1 h. The cell nuclei were stained with 4′,6-diamidino-2-
phenylindole, washed repeatedly with PBS, and fluorescence was ob-
served under a fluorescence microscope (Nikon ECLIPSE TS100 fluor-
escence microscope, Nikon, Japan).
Fig. 1. The chemical structure of compounds. A. AVN-944. Molecular
weight= 477.51 g/mol. B. mycophenolate mofetil. Molecular
weight= 433.49 g/mol. C. Teriflunomide. Molecular weight =270.51 g/mol.
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2.7. Q-PCR assay
For relative quantification of viral mRNA synthesis, the total RNA
from the harvested cells was isolated using TRIzol reagent (Invitrogen).
The RNA was eluted in 50 μL of RNase-free water and treated with
PrimeScript™ RT reagent kit containing gDNA Eraser (Takara, Dalian,
China) to eliminate DNase I, according to the manufacturer’s instruc-
tions. Subsequently, the total RNA was reverse transcribed with random
hexamer primers using Agilent Technologies Stratagene Mx3005 P in-
strument (Agilent, USA) and SYBR Premix Ex TaqTMII (Tli RNaseH
Plus) (TaKaRa, Dalian, China) with a reaction volume of 25 μL. The
relative expression of the FMDV 2B (forward, 5′-CAACAAAACACGGA
CCCGAC-3′; reverse, 5′-TTGTACCAGGGTTTGGCCTC-3′) was de-
termined by normalizing against the porcine β-actin gene (forward,
5′-GACCACCTTCAACTCGATCA-3′; reverse, 5′-GTGTTGGCGTAGAGGT
CCTT-3′).
2.8. Western blot analysis
The cell lysates were separated by 12% SDS-PAGE and transferred
to a polyvinylidene difluoride membrane (Millipore, USA). The mem-
brane was blocked with 5% non-fat milk powder in TBST buffer (20mM
Tris−HCl, pH 7.4, 150mM NaCl, 0.1% Tween-20) and then probed
with anti-FMDV VP1 antibody as described previously [13], or with
anti-β-actin antibody (Sigma-Aldrich, USA). The bound antibody was
detected using HRP-conjugated secondary antibodies and visualized by
enhanced chemiluminescence (GE Healthcare).
2.9. Invivo Experiments
In vivo experiments were performed with specific pathogen-free
3–4 day-old BALB/c suckling mice (Lanzhou Veterinary Research
Institute, China). The 50% lethal dose (LD50) of FMDV was estimated by
Reed-Muench method. The BALB/c mice were infected with 100 μL of
100 LD50 of FMDV O/MY98/BY/2010. Subsequently, 60 μg of AVN944,
mycophenolate mofetil, and teriflunomide were respectively dissolved
in PBS containing 100 μM DMSO and 5% Tween-80, and sub-
cutaneously administered to the mice for 2 h at the time of virus ex-
posure. The placebo controls received 100 μL of solvent, while the virus
controls and normal controls received no viral infection and test com-
pounds treatment. The mice were observed for 96 h after infection.
2.10. Histopathology
Heart tissues from solvent-treated (n= 4), solvent-treated FMDV-
infected (n=4), and AVN944-treated FMDV-infected (n= 4) mice
were fixed in 10% formalin for 48 h at room temperature, sectioned,
conventionally stained with hematoxylin and eosin, and examined.
2.11. Statistical analyses
The data were processed using GraphPad Prism 5 and expressed as
means ± S.D. Statistical differences between the two groups were de-
termined using Student's t-test. For multiple groups, one-way ANOVA
was employed to compare the means, and p < 0.05 indicated sig-
nificant difference between the groups.
3. Results
3.1. Cytotoxic effects of the compounds on IBRS-2 cells
The test compounds were examined for cytotoxicity before assessing
their antiviral activities. As shown in Fig. 2A, D and G, the compounds
were differentially cytotoxic. While mycophenolate mofetil, at the ex-
amined concentrations, did not produce a cytotoxic effect on IBRS-2
cells, AVN944 (< 100 μM), and teriflunomide (< 400 μM) failed to
distinctly affect cell viability following treatment for 72 h. However, a
higher concentration of AVN944 and teriflunomide exhibited sig-
nificant dose-dependent cytotoxic effects on IBRS-2 cells, when com-
pared with the DMSO-treated control. The 50% cytotoxic concentration
(CC50) of AVN944 and teriflunomide on IBRS-2 cells were 88.18 μM and
542.7 μM, respectively.
3.2. Antiviral activity of the compounds against FMDV invitro
Based on the results of cytotoxicity of the test compounds, a non-
toxic concentration was employed to explore the antiviral activity of
these compounds against FMDV. The cells were infected with 100
TCID50 of FMDV and incubated with different concentrations of the test
compounds for 48 h. The results revealed that viral replication was
inhibited by the test compounds in a dose-dependent manner. The EC50
of AVN944, mycophenolate mofetil, and teriflunomide were 12.02 μM,
8.142 μM, and 294.1 μM against FMDV O/MY98/BY/2010, respec-
tively, and the selectivity indices (SI) were 7.33, 12.28, and 1.84, re-
spectively. Besides, the test compounds also showed significant in vitro
antiviral activities against another strain of FMDV (A/GD/MM/2013).
The EC50 values of AVN944, mycophenolate mofetil, and teriflunomide
against FMDV A/GD/MM/2013 in IBRS-2 cells were 3.953 μM,
6.500 μM, and 104.9 μM, yielding SI values of 22.30, 15.38, and 5.17,
respectively (Fig. 2B, E, and H). Interestingly, the SI values of the test
compounds against FMDV A/GD/MM/2013 were higher than those
against FMDV O/MY98/BY/2010. The antiviral activities of these
compounds were also analyzed by qPCR and immunofluorescence assay
(IFA). As shown in Fig. 2C, F, and I, treatment with various con-
centrations of the test compounds for 48 h inhibited viral replication in
a dose-dependent manner, as quantified by the relative levels of the
FMDV 2B gene expression. Consistently, the number of FMDV-positive
cell foci presented a corresponding decrease in a dose-dependent
manner, as indicated by indirect IFA (Fig. 3).
3.3. Effects of Guanosine/Uridine on the antiviral activity of the compounds
To further address whether guanosine/uridine could block the ac-
tivity of the test compounds, the infected cells treated with or without
the test compounds were supplemented with serial dilutions of gua-
nosine/uridine. Notably, FMDV VP1 protein levels recovered following
guanosine supplementation in cells treated with mycophenolate mofetil
and AVN944 (Fig. 4B and C), indicating that the antiviral mechanism of
these compounds involved depletion of the purine nucleotide pool.
Likewise, uridine also presented similar effect on teriflunomide-medi-
ated suppression of FMDV replication (Fig. 4D), suggesting that in-
hibition of DHODH is the major antiviral mechanism of teriflunomide
against FMDV infection.
3.4. Time course assay
Time course assay was used to examine the stages of FMDV re-
plication that were affected by the test compounds (Fig. 5). The test
compounds were added during viral infection (0 h post-infection) or
after viral infection (2–16 h post-infection). The mRNA and VP1 protein
changes in the IBRS-2 cells were analyzed at 48 h post-infection. As
shown in Fig. 5, the compounds could considerably reduce 2B mRNA
and VP1 protein levels until 8 h post-infection; however, no significant
inhibitory effect on FMDV replication was observed after 16 h of viral
adsorption. Taken together, these results suggested that the tested in-
hibitors constrained FMDV replication in vitro at the early stage of
infection.
3.5. Invivo Experiments
Based on the anti-FMDV potency of the inhibitors in vitro, their
protective efficacy against lethal FMDV infection in suckling mice was
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further explored. Three-day-old suckling mice were injected with FMDV
O/MY98/BY/2010 strain at a dose of 100 LD50, followed by treatment
with the test compounds. As shown in Fig. 6, the suckling mice in the
control group began to die at 36–60 h. Among the treatment groups, the
suckling mice in the AVN-944 and teriflunomide treatment groups
began to die at 72 h and 60 h, respectively. The infected mice in the
mycophenolate mofetil treatment group began to die at 36 h, and the
death time decreased subsequently (P＝ 0.02). At 96 h post-infection,
the survival rates of mice in the AVN-944, mycophenolate mofetil, and
teriflunomide treatment groups were 25%, 8.3%, and 25%, respec-
tively. Although mycophenolate mofetil injection showed a higher
survival rate, no statistical significance were found between the control
and the drug-treated groups (P＝0.02). Larger studies are needed for a
significant difference in the survival rate between the two groups.
While, subcutaneous administration of AVN-944 and teriflunomide
significantly improved the survival rates of infected mice, when com-
pared with the virus control group. In particular, AVN944 showed su-
perior activity using the same dose, when compared with the treatment
of teriflunomide. Therefore, the protective effects of AVN944 against
FMDV-induced tissue damage were further examined through histo-
pathology analysis. As shown in Fig. 7, myocardial fiber dissolution and
inflammatory cell infiltration were observed in the hearts of virus
control mice without inhibitors treatment (Fig. 7C and F), whereas no
obvious inflammatory symptoms were noted in AVN944-treated in-
fected mice (Fig. 7B and E).
4. Discussion
In general, vaccination is considered as the gold standard for con-
trolling viral diseases; however, the use of antiviral drugs for the con-
trol of highly mutagenic viruses such as FMDV is still limited. As
commercially available vaccines do not provide early protection for
virus-infected animals, the World Organization for Animal Health (OIE)
recommends the use of a combination of vaccines and antiviral drugs to
effectively control viruses [15]. It is therefore very important to un-
cover antiviral agents for FMDV treatment. In recent years, increasing
evidences have indicated that targeting DHODH and IMPDH may be a
promising strategy to develop broad-spectrum antiviral drugs.
AVN944 is a highly selective, non-nucleoside, specific, un-
competitive IMPDH inhibitor, which was developed by Vertex (VX-944)
and licensed by Avalon Pharmaceuticals (AVN944) [16]. AVN944 has
been demonstrated to be well-tolerated by humans, and is currently
under clinical trials on patients with hematological malignances and, in
combination with gemcitabine, on patients with pancreatic cancer [17].
Fig. 2. Compounds potently inhibits FMDV infection in IBRS-2 cells. (A, D, G) Cytotoxicity of compounds on IBRS-2 cells. MTS assays were performed to assess
IBRS-2 cells viability after 72 h of treatment with AVN-944 (A), mycophenolate mofetil (D), teriflunomide (G), respectively. Data are expressed as mean ± SD of the
percentage values obtained from three independent experiments carried out in triplicate. (B, E, H) IBRS-2 cells were infected with 100 TCID50 FMDVs (O/MY98/BY/
2010 or A/GD/MM/2013) for 1 h and then treated with increasing concentrations of compounds. 48 h after treatment, antiviral activity was determined by the
reduction of the cytopathic effect in an MTS assay. Cell viability of DMSO-treated cells was set to 0% and that of uninfected cells was set 100%. (C, F, I) Total RNAs
were prepared from cells in (B, E, H) and then subjected to Q-PCR for 2B region of FMDV viral RNA. β-actin mRNAs were also analyzed as a negative control. Data are
expressed as mean ± SD of the percentage values obtained from three independent experiments carried out in triplicate. ***P < 0.001.
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Mycophenolic mofetil, a prodrug of mycophenolic acid, is a non-com-
petitive inhibitor of IMPDH, and has been approved by the FDA for
immune suppression. In addition, it has been reported to inhibit H5N1
virus replication in MDCK cells and mice [18]. Teriflunomide, a prin-
cipal active metabolite of leflunomide, is a novel oral im-
munomodulator with anti-inflammatory properties, and is used for the
treatment of patients with relapsing forms of multiple sclerosis and
rheumatoid arthritis [19,20]. Besides its anti-inflammatory effects,
teriflunomide has also been found to exert antiviral activities against
numerous viruses, including Theiler’s murine encephalomyocarditis
virus [21], Epstein-Barr virus [22], Newcastle disease virus, and Ebola
virus [23]. To the best of the authors’ knowledge, the present study is
the first to demonstrate the antiviral activity of AVN944, mycophenolic
mofetil, and teriflunomide against FMDV.
With regard to FMDV epidemic, besides type O FMDV, type A FMDV
is also widely disseminated in China [24]. To explore whether the an-
tiviral activity of the tested compounds is strain-dependent, the effect of
these inhibitors on type A FMDV (A/GD/MM/2013) was evaluated. The
results demonstrated that the compounds could also inhibit type A
FMDV infection in IBRS-2 cells, supporting that the tested IMPDH and
DHODH inhibitors exerted broad-spectrum antiviral activities. In future
studies, the effect of these compounds on other FMDV genotypes or
strains must be investigated. Considering their characteristics, both
IMPDH and DHODH could be promising candidates for the treatment of
other viral diseases, such as enterovirus-A71 (which belongs to the
same family (Picornaviridae) as FMDV) and African swine fever (ASF;
Fig. 3. The viral proteins were determined
by IFA. IBRS-2 cells were infected by 100
TCID50 FMDV O/MY98/BY/2010, with or
without treatment by various concentrations of
compounds for 12 h. The green fluorescence
represents the intracelluar distribution of
FMDV visualized by DAPI staining. Scale bars
indicate 100 μm (For interpretation of the re-
ferences to colour in this figure legend, the
reader is referred to the web version of this
article).
Fig. 4. Guanosine or uridine attenuated the
antiviral activity of compounds. A.
Schematic overview of de novo biosynthesis of
purine and pyrimidine nucleotide. (B, C)
FMDV-infected IBRS-2 cells were treated with
AVN-944 (50 μM) or mycophenolate mofetil
(50 μM) in the presence of exogenous guano-
sine. (D) FMDV-infected IBRS-2 cells were
treated with teriflunomide (300 μM) in the
presence of exogenous uridine, as indicated.
Cells were incubated for 48 h, total cell extracts
were prepared from cells and subjected to
Western Blot analysis with anti-VP1 antibody.
β-actin was also analyzed as a loading control.
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another disease listed by OIE similar to FMD). Since the first reported
ASF case in China in 2018, over 100 ASF cases had been recorded in 23
provinces or regions of China [25]. ASF has caused a severe threat to
the domestic pig population in China, resulting in huge economic loss.
With the current lack of vaccines to control ASF, there is a need to
consider alternative control strategies, including IMPDH and DHODH
as potential targets for antiviral drug development. Interestingly, it has
been indicated that targeting other catalytic steps leading to primary
purine nucleotide synthesis may stimulate viral replication (e.g. hepa-
titis E virus (HEV)) [26]. For example, Wang et al. reported that in-
hibition of amido phosphoribosyltransferase, glycinamide ribonucleo-
tide transformylase, 5-aminoimidazole-4-carboxamide ribonucleotide
formyltransferase, and IMP cyclohydrolase promoted HEV replication
[26]. In our future study, we will test the effects of inhibition of these
enzymes on FMDV infection. In fact, besides the inhibition of nucleotide
synthesis, disruption of protein translation may also be a potential
antiviral therapeutic strategy to control infection because viral
Fig. 5. Antiviral activity of compounds de-
pending on the time of addition. IBRS-2 cells
were infected with 100 TCID50 FMDV O/
MY98/BY/2010 and treated with 50 μM of
AVN-944 (A, B), mycophenolate mofetil (C, D)
or 300 μM teriflunomide (E, F) at the indicated
times after virus infection, respectively. 48 h
post-infection, total cell extracts were prepared
from cells and subjected to Q-PCR and Western
Blot analysis with anti-VP1 antibody, respec-
tively. β-actin was also analyzed as a loading
control. Data are expressed as mean ± SD of
the percentage values obtained from three in-
dependent experiments carried out in tripli-
cate. *P < 0.05, ***P < 0.001.
Fig. 6. in vivo activity of compounds. Suckling mice were challenged with 100
LD50 of FMDV O/MY98/BY/2010 after 2 h pre-treatment with 60 μg of AVN-
944, mycophenolate mofetil and teriflunomide, respectively. The survival rate
of suckling mice was monitored for 96 h post-challenge.
Fig. 7. Histological analysis of heart tissue
stained with hematoxylin and eosin (H&E)
in suckling mouse. The suckling mouse was
treated with the placebo or 60 μg AVN-944.
The pathological changes of heart tissues at
30 hpi were observed after H & E staining.
Representative H&E stained samples of heart
tissue from (A, D) health, (B, E) AVN-944-
treated, and (C, F) placebo-treated are shown
(N=4). A, B, C (magnification, 100×); D, E, F
(magnification, 400×).
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replication also relies on cellular translational machinery. For instance,
halofuginone, a potent prolyl tRNA synthetase inhibitor, has been de-
monstrated to suppress Chikungunya and Dengue viral infections [27]
as well as FMDV replication (unpublished).
In the present study, to further investigate the stage of FMDV re-
plication that is sensitive to the tested inhibitors, the IBRS-2 cells were
exposed to these compounds at various time points after virus entry.
While the addition of these compounds to the infected cells significantly
suppressed FMDV replication before 8 h post-infection, no significant
inhibitory effects were noted after 16 h post-infection. The results of
time-course study suggested that all the three tested compounds ex-
hibited inhibitory effects on the early stages of FMDV replication cycle.
One of the well-recognized antiviral mechanisms of inhibitor com-
pounds is disruption of IMPDH/DHODH to deplete the intracellular
GTP or pyrimidine pools [26]. To determine whether this mechanism is
involved in FMDV inhibition, guanosine/uridine was added to the in-
fected cells treated with inhibitors. While guanosine/uridine alone had
no effect, they significantly attenuated the anti-FMDV effects of these
compounds, suggesting that nucleotide depletion by inhibitors is an
important mechanism in controlling FMDV infection. In recent years,
other novel potential mechanisms have been reported; for example,
some IMPDH and DHODH inhibitors have also been noted to enhance
the innate immune responses triggered by short 5′-triphosphate RNA
molecules as measured by IFN-stimulated response element reporter
and IFN-stimulated expression of downstream genes, such as IFN-in-
duced protein with tetratricopeptide repeats 1 and IFN regulatory
factor 1, thus further contributing to their antiviral activities [28].
However, in general, treatment with individual antiviral agents cannot
achieve complete inhibition of viruses owing to limitations related to
viral resistance, such as amino acid substitutions against mutagens [6].
It has been proposed that treatment with a combination of antiviral
agents with different mechanisms might be more advantageous in
overcoming their individual limitations. Similarly, combinations of
IMPDH inhibitor and nucleoside analog have been reported to present
synergistic benefits in treating several viruses [29].
Although IMPDH and DHODH inhibitors have been noted to show
antiviral activity against some viruses, many of them have failed to
exhibit promising antiviral effects in animal models. However, in the
present study, the effects of the test compounds were also observed in
the animal experiment, and the suckling mice treated with these com-
pounds exhibited higher survival rates, when compared with the con-
trol group. Interestingly, treatment with AVN944 was more effective
than treatments with mycophenolate mofetil and teriflunomide.
Therefore, in future studies, the antiviral efficacy of these compounds
should be further investigated in relevant species such as pigs and
cattle. Choi et al. reported that the combination of ribavirin and vaccine
presented a synergistic effect on the early stage of FMDV replication
[30]. Hence, the effects of combinations of antiviral agents and novel
FMD vaccines on possible early protection against viral infection prior
to the establishment of host immunity through vaccination must be
explored.
In conclusion, the results of the present study demonstrated the
effective antiviral activities of AVN944, mycophenolate mofetil, and
teriflunomide against FMDV, and their underlying initial antiviral me-
chanisms. Future research should focus on assessing the activities of
these compounds in natural hosts as well as their efficacies in combi-
nation with vaccines.
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